Form 4: Director Valerie Jansen Receives OnKure Stock Options

Director Valerie Malyvanh Jansen was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Summary

• Valerie Malyvanh Jansen, a Director at OnKure Therapeutics, Inc. (OKUR), was granted 7,650 stock options.
• The options have an exercise price of $4.30 per share.
• The grant date for the transaction was June 4, 2026.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying Class A Common Stock.
• Vesting is contingent upon the director remaining a service provider to the company.

Future Outlook

The options vest on the earlier of June 4, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common industry standard for board members.

Stakeholder Impact

• Minor potential dilution for shareholders upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 4, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Trading, Stock Options, Director Compensation